V体育平台登录 - Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official VSports app下载. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Meta-Analysis
. 2015 Mar;32(3):149-57.
doi: 10.1002/da.22329. Epub 2014 Nov 28.

Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis

Jeffrey R Strawn  1 , Jeffrey A Welge, Anna M Wehry, Brooks Keeshin, Moira A Rynn
Affiliations
Meta-Analysis

Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis

Jeffrey R Strawn et al. Depress Anxiety. 2015 Mar.

Abstract (V体育官网入口)

Background: Randomized controlled trials have demonstrated that antidepressants are efficacious in the treatment of anxiety disorders in youth. However, there are no recent, systematic analyses of the efficacy, safety, or tolerability of these medications in pediatric anxiety disorders VSports手机版. .

Methods: A systematic review and meta-analysis of prospective, randomized, parallel-group, controlled trials of selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SSNRIs) in pediatric patients with non-obsessive compulsive disorder (OCD) anxiety disorders was undertaken using a search of PubMed/Medline (1966-2014). The meta-analysis utilized random-effects models to evaluate change in the Pediatric Anxiety Rating Scale or similar anxiety scale, suicidality, and adverse events V体育安卓版. Additionally, pharmacologic variables were explored with regard to effect size, although no correction for multiple comparisons was made with regard to these relationships. .

Results: Nine trials involving 1,673 patients and six medications were included. All SSRI/SSNRIs evaluated demonstrated efficacy, and the meta-analytic estimate of effect was of moderate magnitude (Cohen's d = 0. 62, confidence interval [CI]: 0. 34-0. 89, P = V体育ios版. 009) and there was evidence of modest heterogeneity (I(2) = 0. 29, P = . 103). Activation trended toward being more likely with antidepressant treatment (OR: 1. 86, CI: 0. 98-3. 53, P = . 054), but no increased risk was observed for nausea/abdominal symptoms (P = . 262), discontinuation as a result of an adverse event (P = . 132), or suicidality (OR: 1. 3, CI: 0. 53-3. 2, P = . 514). Finally, the effect size correlated with the serotonergic specificity of the agent (R = . 79, P = . 021). .

Conclusions: Data for nine SSRI/SSNRIs suggest superiority of antidepressants relative to placebo for the treatment of pediatric anxiety disorders with a moderate effect size. VSports最新版本.

Keywords: GAD; antidepressants; anxiety; anxiety disorders; child/adolescent; generalized anxiety disorder; pharmacotherapy; separation anxiety V体育平台登录. .

PubMed Disclaimer

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flow Diagram.
Figure 2
Figure 2. Funnel plot (A) and forest plot (B) for individual studies of selective serotonin reuptake inhibitors (SSRIs) and selective serotonin norepinephrine reuptake inhibitors in children and adolescents with generalized anxiety disorder, social phobia or separation anxiety disorder
Effect sizes are based on the change in the dimensional anxiety symptom scale from baseline (see methods) and open symbols represent effect sizes and horizontal lines reflect the 95% confidence intervals for each study. Dashed line represents the estimated effect size (Cohen's d=0.62)
Figure 3
Figure 3. Effect size is predicted by serotonergic selectivity in double-blind, placebo-controlled trials of antidepressants in youth with anxiety disorders
Serotonergic specificity is reflected by the ratio of the Ki for norepinephrine to the Ki for serotonin, where Ki is the inhibition constant (in nM), based on radioactive ligand transport competition assays using human specific transporter proteins. Note: potency is inversely related to Ki and, given that concurrent treatment with psychostimulants (which affect norepinephrine and dopamine) was allowed in the trial by March et al, 2008, this study was excluded.
See this image and copyright information in PMC

References

    1. Blackford JU, Pine DS. Neural substrates of childhood anxiety disorders: a review of neuroimaging findings. Child Adolesc Psychiatr Clin N Am. 2012;21(3):501–25. - PMC - PubMed
    1. Beesdo K, Pine DS, Lieb R, Wittchen HU. Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch Gen Psychiatry. 2010;67(1):47–57. - PubMed
    1. Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, Bridge J, Heo J, Brent DA. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003;42(4):415–423. - PubMed
    1. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;(297):1683–1696. - "V体育安卓版" PubMed
    1. Compton SN, Walkup JT, Albano AM, Piacentini JC, Birmaher B, Sherrill JT, Ginsburg GS, Rynn MA, McCracken JT, Waslick BD, Iyengar S, Kendall PC, March JS. Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods. Child Adolesc Psychiatry Ment Health. 2010;4:1. - PMC - PubMed

Publication types

MeSH terms

Substances